ProMIS Neurosciences Inc PMN

Seems to be room for others in AD Treatment

[retiredcop]

https://www.investors.com/news/technology/biogen-stock-flies-on-upgrade-why-alzheimers-is-a-billions-opportunity/

[FarmerBetty]

RC, you should think about posting on Biogen's blogs where you could be poster boy for them. I thiink most people have heard enough about Biogen!

[G1945V]

Question for the medics on this forum.  Mechanism of action (MOA) for : "Lecanemab  (BAN2401)  selectively binds to neutralize and eliminate soluble, toxic amyloid-beta (Aβ) aggregates (protofibrils) that are thought to contribute to the neurodegenerative process in AD. As such, lecanemab may have the potential to have an effect on disease pathology and to slow down the

[M101]

Great question for the new CEO as it exemplifies the main failing of the old CEO to differentiate in a way suitable for retail investors. Such investors need a bold statement describing how the competition is limited by not utilizing fold-specific exposed epitopes, i.e., why the misfolding is critical.   It's not enough to have the information available in academic papers or inferred

[Gbathat]

Yes, similar mechanism. Likely significant different binding targets at the amino acid level. PMN310 does not bind quite as strongly as lecanumab but binds better or similar than aducanumab and others. However, PMN310 is more selective, in that it binds less to plaque and other targets, making it much less likely to cause ARIA-E brain swelling, which limits the dosing of aducanumab and